411 related articles for article (PubMed ID: 33483918)
1. Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis.
Yamaguchi T; Kohyama N; Takenaka M; Okada T; Kurihara T; Sakurai K; Miwa Y; Kogo M
Clin Rheumatol; 2021 Jul; 40(7):2657-2663. PubMed ID: 33483918
[TBL] [Abstract][Full Text] [Related]
2. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
[TBL] [Abstract][Full Text] [Related]
3. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.
Aramaki T; Ueki Y; Kojima K; Kurushima S; Tsuji Y; Kawachi N; Iwamoto N; Ichinose K; Terada K; Eguchi K; Kawakami A
Mod Rheumatol; 2020 Jan; 30(1):50-57. PubMed ID: 30482075
[No Abstract] [Full Text] [Related]
5. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
[TBL] [Abstract][Full Text] [Related]
6. Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort.
Moura CS; Schieir O; Valois MF; Thorne C; Bartlett SJ; Pope JE; Hitchon CA; Boire G; Haraoui B; Hazlewood GS; Keystone EC; Tin D; Bykerk VP; Bernatsky S;
Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1104-1111. PubMed ID: 31112011
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
Katchamart W; Trudeau J; Phumethum V; Bombardier C
Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD008495. PubMed ID: 20393970
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.
Santos-Moreno PI; de la Hoz-Valle J; Villarreal L; Palomino A; Sánchez G; Castro C
Clin Rheumatol; 2015 Feb; 34(2):215-20. PubMed ID: 25318612
[TBL] [Abstract][Full Text] [Related]
9. Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs: Results from a retrospective cohort study.
Floris A; Perra D; Cangemi I; Congia M; Chessa E; Angioni MM; Mangoni AA; Erre GL; Mathieu A; Piga M; Cauli A
Medicine (Baltimore); 2021 Apr; 100(17):e25481. PubMed ID: 33907096
[TBL] [Abstract][Full Text] [Related]
10. [Re-recognition of methotrexate monotherapy in rheumatoid arthritis].
Dai LY; Zhao JX
Zhonghua Yi Xue Za Zhi; 2022 Oct; 102(37):2909-2913. PubMed ID: 36207865
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
12. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
13. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
[TBL] [Abstract][Full Text] [Related]
14. The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis.
Hetland ML; Hørslev-Petersen K
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S44-9. PubMed ID: 23079125
[TBL] [Abstract][Full Text] [Related]
15. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
18. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
20. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]